Prevalence of potential drug-drug interactions among intensive care unit patients receiving linezolid: a cross-sectional study

H.-Y. Jiang, L.-Y. Yu, X. Wang, Z.-W. Yu, Y.-H. Zhao

Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. yzw_srrsh@zju.edu.cn

---

• Pharmacology

OBJECTIVE: Linezolid is commonly used in intensive care units (ICU) but has the potential to interact with other drugs. This study aimed to evaluate the prevalence of potential drug-drug interactions in ICU patients receiving linezolid.

PATIENTS AND METHODS: Data of ICU patients receiving linezolid were extracted and included in the Hospital Prescription Analysis Program of China, and the risk of potential drug-drug interactions between concomitant drugs and linezolid was evaluated using the Lexicomp database.

RESULTS: A total of 3,712 ICU patients from 59 hospitals were included in the analysis, and patients received an average of 17 concomitant drugs. A total of 67.9% of patients had potential drug-drug interactions. Patients receiving concomitant drugs with risk ratings of “X”, “D”, and “C” categories were 20.8%, 30.4%, and 35.1%, respectively. Opioids were the most frequently prescribed drug class with drug-drug interactions (DDIs) in the “X” category, whereas butorphanol, metoclopramide, and sufentanil were the most contraindicated concomitant drugs.

CONCLUSIONS: ICU patients receiving linezolid have a high prevalence of potential drug-drug interactions, and efforts should be made to better recognize and manage this risk.

Free PDF Download